Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04630444 · ClinicalTrials.gov registry record · Early Phase 1

Riluzole Effects on Hippocampus Biomarkers

A Early Phase 1 study, sponsored by Mclean Hospital.

Completed
Registry status
Early Phase 1
Development phase
20
Enrollment target

NCT04630444: Completed Early Phase 1 study, sponsored by Mclean Hospital.

NCT04630444 is a Early Phase 1 study that has completed, run by Mclean Hospital. The registered enrollment target is 20 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04630444, a Early Phase 1 study, has completed, sponsored by Mclean Hospital.

COMPLETED
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target

Study Summary

To examine the clinical efficacy of the anti-glutamatergic medication riluzole in posttraumatic stress disorder (PTSD), and its effect on hippocampus biomarkers that our laboratory previously has identified using MRS.

Primary Outcome

Testing the hypothesis that riluzole monotherapy will yield within-subject reductions in PTSD total symptoms (CAPS total score)

Interventions

  • DRUG Riluzole

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2017-03-16
Est. Completion 2019-03-16
Phase Early Phase 1
Mclean Hospital

140 total trials

What the finished NCT04630444 record still lists

NCT04630444 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower).

The record links to 0 conditions, and to 1 intervention - of which Riluzole is the first listed.

NCT04630444 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04630444 about?

NCT04630444 is a clinical study titled "Riluzole Effects on Hippocampus Biomarkers". To examine the clinical efficacy of the anti-glutamatergic medication riluzole in posttraumatic stress disorder (PTSD), and its effect on hippocampus biomarkers that our laboratory previously has identified using MRS.

What is the current status of trial NCT04630444?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2017-03-16. Estimated completion is 2019-03-16.

What interventions are being tested in trial NCT04630444?

The interventions under investigation include: Riluzole (DRUG).

Who is sponsoring clinical trial NCT04630444?

This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04630444's enrollment target sits among peer trials

20 1157th of 2000 higher than 710 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04630444, the US trial registry maintained by the National Library of Medicine. NCT04630444 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.